{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:58:32Z","timestamp":1775239112473,"version":"3.50.1"},"reference-count":69,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,3,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fibrotic interstitial lung diseases (fILDs) are chronic lung diseases with rising incidence and prevalence. Patients affected become increasingly breathless, dependent on supplementary oxygen and generally die from respiratory failure. Despite the availability of antifibrotic therapies, treatment options that can positively impact the quality of life of patients with fILD remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the current clinical trial landscape in fILD, and explore emerging strategies to accelerate the development of therapies that improve outcomes that are meaningful to patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>There is growing recognition that advances in clinical trial design and endpoint selection are needed to better and more quickly evaluate investigational therapies to improve outcomes for patients with this often-devastating disease. There is increasing interest in incorporating endpoints that reflect on how the patient feels, functions and survives rather than a singular focus on forced vital capacity changes, which currently is a widely accepted endpoint for clinical trials for fILD. To accelerate the development of more effective therapies for these patients, innovative approaches to fILD clinical trial designs are needed. Approaches such as biomarker-based cohort enrichment, incorporation of alternative endpoints, use of adaptive and\/or platform trial designs and decentralisation of studies can enhance the efficiency of clinical trials. Furthermore, engaging and aligning key stakeholders, most importantly patients, is crucial to ensure that outcomes important to the patients are addressed in the trial design. This review examines the current status of clinical trials in fILD, highlights the limitations of traditional clinical trial design approaches and explores potential strategies to accelerate the path towards improved treatments and outcomes for patients living with fILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2024-222057","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:20:20Z","timestamp":1775236820000},"page":"thorax-2024-222057","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-4988","authenticated-orcid":false,"given":"Tejaswini","family":"Kulkarni","sequence":"first","affiliation":[{"name":"The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Funke-Chambour","sequence":"additional","affiliation":[{"name":"Pulmonology, Allergology and Clinical Immunology, Inselspital University Hospital Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[{"name":"European Pulmonary Fibrosis Federation, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Rivera-Ortega","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Service, Respiratory Medicine Department, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-6808","authenticated-orcid":false,"given":"Sydney","family":"Montesi","sequence":"additional","affiliation":[{"name":"Medicine, Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2026040310201082000_thorax-2024-222057v1.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026040310201082000_thorax-2024-222057v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705751"},{"key":"2026040310201082000_thorax-2024-222057v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026040310201082000_thorax-2024-222057v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026040310201082000_thorax-2024-222057v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026040310201082000_thorax-2024-222057v1.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0509PP"},{"key":"2026040310201082000_thorax-2024-222057v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2026040310201082000_thorax-2024-222057v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500526"},{"key":"2026040310201082000_thorax-2024-222057v1.9","unstructured":"Raghu G , Ghazipura M , Fleming TR , et al . Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on \u2019Feels, Functions, Survives. Am J Respir Crit Care Med 2024."},{"key":"2026040310201082000_thorax-2024-222057v1.10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2024.8693","article-title":"Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial","volume":"332","author":"Raghu","year":"2024","journal-title":"JAMA"},{"key":"2026040310201082000_thorax-2024-222057v1.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5355"},{"key":"2026040310201082000_thorax-2024-222057v1.12","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1164\/rccm.202401-0116OC","article-title":"Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial","volume":"209","author":"Richeldi","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1164\/rccm.202307-1154WS","article-title":"Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report","volume":"209","author":"Montesi","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.chest.2017.09.026","article-title":"Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort","volume":"153","author":"Adegunsoye","year":"2018","journal-title":"Chest"},{"key":"2026040310201082000_thorax-2024-222057v1.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01575-2024"},{"key":"2026040310201082000_thorax-2024-222057v1.16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02163-2022","article-title":"Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study","volume":"61","author":"Khor","year":"2023","journal-title":"Eur Respir J"},{"key":"2026040310201082000_thorax-2024-222057v1.17","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1001\/jama.2021.4956","article-title":"Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial","volume":"325","author":"Martinez","year":"2021","journal-title":"JAMA"},{"key":"2026040310201082000_thorax-2024-222057v1.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22960"},{"key":"2026040310201082000_thorax-2024-222057v1.19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1164\/rccm.201903-0592PP","article-title":"Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies","volume":"200","author":"Kaner","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.20","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in Patients with Progressive Pulmonary Fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026040310201082000_thorax-2024-222057v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108"},{"key":"2026040310201082000_thorax-2024-222057v1.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2026040310201082000_thorax-2024-222057v1.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-571OC"},{"key":"2026040310201082000_thorax-2024-222057v1.24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201737"},{"key":"2026040310201082000_thorax-2024-222057v1.26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026040310201082000_thorax-2024-222057v1.27","unstructured":"Pliant Therapeutics Provides Update on BEACON-IPF. PLIANT, 2025. Available: https:\/\/ir.pliantrx.com\/news-releases\/news-release-details\/pliant-therapeutics-provides-update-beacon-ipf\/ [Accessed 26 Mar 2026]."},{"key":"2026040310201082000_thorax-2024-222057v1.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0006PP"},{"key":"2026040310201082000_thorax-2024-222057v1.29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026040310201082000_thorax-2024-222057v1.30","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/resp.14579","article-title":"Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis","volume":"28","author":"Maher","year":"2023","journal-title":"Respirology"},{"key":"2026040310201082000_thorax-2024-222057v1.31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/17476348.2020.1816831","article-title":"Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons","volume":"15","author":"Nathan","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2026040310201082000_thorax-2024-222057v1.32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.chest.2025.07.4078","article-title":"Geographical Distribution of Phase II\/III Pharmaceutical Randomized Controlled Trials in Adults With Interstitial Lung Disease","volume":"169","author":"Guan","year":"2026","journal-title":"Chest"},{"key":"2026040310201082000_thorax-2024-222057v1.33","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1164\/rccm.202509-2336ST","article-title":"Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement","volume":"211","author":"Assayag","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.34","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2589-7500(22)00173-X","article-title":"Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort","volume":"4","author":"Fainberg","year":"2022","journal-title":"Lancet Digit Health"},{"key":"2026040310201082000_thorax-2024-222057v1.35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","article-title":"Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis","volume":"209","author":"Oldham","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.36","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.202312-2274LE","article-title":"e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial","volume":"209","author":"Devaraj","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.37","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026040310201082000_thorax-2024-222057v1.38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202107-1769OC"},{"key":"2026040310201082000_thorax-2024-222057v1.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir Res"},{"key":"2026040310201082000_thorax-2024-222057v1.40","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217315"},{"key":"2026040310201082000_thorax-2024-222057v1.41","doi-asserted-by":"crossref","first-page":"745233","DOI":"10.3389\/fimmu.2021.745233","article-title":"KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2026040310201082000_thorax-2024-222057v1.42","article-title":"Development of a multi-biomarker risk score based on serum proteins by the prognostic lung fibrosis consortium (prolific)","volume":"64","author":"Schafer","year":"2024","journal-title":"European Respiratory Journal"},{"key":"2026040310201082000_thorax-2024-222057v1.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-1934OC"},{"key":"2026040310201082000_thorax-2024-222057v1.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-02281-8","article-title":"Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial","volume":"22","author":"Podolanczuk","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026040310201082000_thorax-2024-222057v1.45","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-221148"},{"key":"2026040310201082000_thorax-2024-222057v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.165"},{"key":"2026040310201082000_thorax-2024-222057v1.47","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202003-192SD"},{"key":"2026040310201082000_thorax-2024-222057v1.48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/23971983241278079","article-title":"Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease","volume":"10","author":"Khanna","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"2026040310201082000_thorax-2024-222057v1.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"2026040310201082000_thorax-2024-222057v1.50","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3538","article-title":"Design and Rationale for a Phase 3 Trial of Admilparant (BMS-986278), An Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Idiopathic Pulmonary Fibrosis: ALOFT-IPF","volume":"211","author":"Maher","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310201082000_thorax-2024-222057v1.51","doi-asserted-by":"crossref","unstructured":"F.J. Martinez TJC , Cottin V , Fischer S . Design and Rationale of a Phase 3 Trial for Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Progressive Pulmonary Fibrosis: ALOFT-PPF. Am J Respir Crit Care Med 2025. doi:10.1164\/ajrccm.2025.211.Abstracts.A3543","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3543"},{"key":"2026040310201082000_thorax-2024-222057v1.52","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-024-01023-w","article-title":"Walk, talk, think, see and feel: harnessing the power of digital biomarkers in healthcare","volume":"7","author":"Powell","year":"2024","journal-title":"NPJ Digit Med"},{"key":"2026040310201082000_thorax-2024-222057v1.53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King\u2019s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference","volume":"6","author":"Sinha","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2026040310201082000_thorax-2024-222057v1.54","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00281-2019","article-title":"King\u2019s Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference","volume":"54","author":"Nolan","year":"2019","journal-title":"Eur Respir J"},{"key":"2026040310201082000_thorax-2024-222057v1.55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0415OC"},{"key":"2026040310201082000_thorax-2024-222057v1.56","doi-asserted-by":"crossref","first-page":"00145","DOI":"10.1183\/23120541.00145-2020","article-title":"The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease","volume":"7","author":"Swigris","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026040310201082000_thorax-2024-222057v1.57","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_100038","article-title":"Why and How to Integrate Early Palliative Care Into Cutting-Edge Personalized Cancer Care","volume":"44","author":"Petrillo","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026040310201082000_thorax-2024-222057v1.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000678"},{"key":"2026040310201082000_thorax-2024-222057v1.59","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134371","article-title":"Making Sense of Composite Endpoints in Clinical Research","volume":"12","author":"Baracaldo-Santamar\u00eda","year":"2023","journal-title":"J Clin Med"},{"key":"2026040310201082000_thorax-2024-222057v1.60","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1513\/AnnalsATS.202303-229RL","article-title":"A Novel Approach to Clinical Change Endpoints: A Win Ratio Analysis of the INCREASE Trial","volume":"20","author":"Nathan","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026040310201082000_thorax-2024-222057v1.61","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-024-00518-x"},{"key":"2026040310201082000_thorax-2024-222057v1.62","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-025-01211-7","article-title":"Diversity in decentralized clinical trials: prioritizing inclusion of underrepresented groups","volume":"26","author":"van Rijssel","year":"2025","journal-title":"BMC Med Ethics"},{"key":"2026040310201082000_thorax-2024-222057v1.63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12890-024-03314-0","article-title":"Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease","volume":"24","author":"Aggarwal","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026040310201082000_thorax-2024-222057v1.64","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2025-1","article-title":"Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011-2013","volume":"18","author":"Jeong","year":"2017","journal-title":"Trials"},{"key":"2026040310201082000_thorax-2024-222057v1.65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.chest.2025.10.009","article-title":"The Global Participation in Interstitial Lung Disease Trials: A Work in Progress","volume":"169","author":"Assayag","year":"2026","journal-title":"Chest"},{"key":"2026040310201082000_thorax-2024-222057v1.66","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202001-035SD"},{"key":"2026040310201082000_thorax-2024-222057v1.67","doi-asserted-by":"crossref","first-page":"00645","DOI":"10.1183\/23120541.00645-2025","article-title":"Factors affecting clinical trial participation in people with interstitial lung disease: a qualitative study","volume":"12","author":"Hoffman","year":"2026","journal-title":"ERJ Open Res"},{"key":"2026040310201082000_thorax-2024-222057v1.68","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00602-2022","article-title":"Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations","volume":"9","author":"Jones","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026040310201082000_thorax-2024-222057v1.69","unstructured":"Gilbert A , ed. Decoding drug development: Patient organisation engagement across the drug life cycle. 8th Systemic Sclerosis World Congress, 2024."}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:20:25Z","timestamp":1775236825000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":69,"alternative-id":["10.1136\/thorax-2024-222057"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222057","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}